Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pharvaris B.V
PHVS | US
28.78
USD-0.36
-1.24%
PHVS | US
About Pharvaris B.V
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
28.78
Open
29.14
High
29.14
Low
28.24
Pharvaris N.V. a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121 a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416 an on-demand rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719 a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands Switzerland and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden the Netherlands.
View LessPHVS | US
Risk
38.9
Sharpe
1.89
Luna's Score
63/100
Recommendation
Hold
Luna says (PHVS | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Smallcap (300M - 2B USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
38.8%1 month
38.9%3 months
43.1%6 months
62.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.17
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-1.38
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-116.10M
MarketCap
1.55B
MarketCap(USD)
1.55B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-45.05
Short ratio
5.12
Short perc.
1.97
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.37
Range1M
4.90
Range3M
5.34
Volumes: Market Activity
Rel. volume
0.56
Price X volume
3.36M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.38 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.17 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 43.11 | - | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 1.55B | - | Emerging |
